文献速递眼底病与葡萄膜炎眼整形与眼眶

BRAF与MEK抑制剂眼部安全性:WHO药物警戒数据库分析

Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
PubMed 文献 · Ophthalmology · 2021-05-14

基于VigiBase数据库2010年1月至2019年10月的回顾性药物警戒研究,纳入1006例BRAF或MEK抑制剂相关眼部不良事件报告。BRAF抑制剂单药与虹膜睫状体异常、前葡萄膜炎等显著相关,MEK抑制剂单药与视网膜脉络膜异常相关,联合治疗可能对弥漫性异常和全葡萄膜炎有协同或 additive 效应。

要点

  • BRAF抑制剂单药与虹膜睫状体异常(ROR 8.7)和前葡萄膜炎(ROR 8.6)报告显著相关。
  • MEK抑制剂单药与视网膜脉络膜异常报告显著相关(ROR 9.5)。
  • BRAF+MEK联合治疗对弥漫性异常和全葡萄膜炎可能有协同或 additive 效应。

核心结论

  • 研究描述了BRAF抑制剂和MEK抑制剂的眼部安全性特征,并识别出若干可能的安全信号。
  • 数据为根据眼部反应类型对BRAF+MEK联合治疗患者进行个性化眼部不良事件管理提供了依据。

研究设计与样本

  • 回顾性、观察性药物警戒研究,使用WHO全球安全数据库VigiBase。
  • 2010年1月至2019年10月共报告1568例BRAF或MEK抑制剂相关眼部不良事件,其中1006例数据充分被纳入分析。
  • 纳入病例中BRAF抑制剂单药310例(30.8%)、MEK抑制剂单药124例(12.3%)、BRAF+MEK联合治疗572例(56.9%)。
  • 采用不均衡分析评估药物与眼部不良事件报告之间的关联,结果以报告比值比(ROR)及其95%置信区间(CI)表示。

主要发现

  • BRAF抑制剂单药与虹膜和睫状体异常(ROR 8.7;95% CI 6.0-12.5)、弥漫性异常(ROR 7.1;95% CI 5.4-9.4)、前葡萄膜炎(ROR 8.6;95% CI 6.0-12.1)和全葡萄膜炎(ROR 7.1;95% CI 5.4-9.4)的报告显著相关。
  • MEK抑制剂单药与视网膜和脉络膜异常(ROR 9.5;95% CI 7.4-12.2)、弥漫性异常(ROR 2.5;95% CI 1.1-6.1)和全葡萄膜炎(ROR 2.5;95% CI 1.1-6.1)的报告相关。
  • BRAF抑制剂与MEK抑制剂联合治疗与来自两类药物的眼部不良事件相关,对弥漫性异常和全葡萄膜炎可能存在协同或 additive 效应。

关键数值与推荐

  • 眼部不良事件根据眼段和炎症模式进行分类,炎症模式基于葡萄膜炎标准化命名(SUN)。
  • BRAF抑制剂单药与虹膜睫状体异常报告的ROR为8.7(95% CI 6.0-12.5)。
  • MEK抑制剂单药与视网膜脉络膜异常报告的ROR为9.5(95% CI 7.4-12.2)。

临床怎么用

  • 对接受BRAF抑制剂单药治疗的患者,应关注虹膜睫状体异常和前葡萄膜炎等眼部不良事件。
  • 对接受MEK抑制剂单药治疗的患者,应关注视网膜脉络膜异常。
  • 对接受BRAF+MEK联合治疗的患者,可根据眼部反应类型进行个性化眼部不良事件管理。

局限性

  • 本研究为回顾性药物警戒数据库分析,可能存在报告偏倚和混杂因素。
  • 部分病例因数据不充分被排除,可能影响结果代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) significantly improved metastatic melanoma prognosis. Ocular adverse effects (OAEs) represent an uncommon but disabling toxicity of these drugs. We aimed to characterize the ocular safety profile of BRAFi or MEKi and to detect possible safety signals. METHODS: We performed a retrospective, observational, pharmacovigilance study using VigiBase, the World Health Organization global safety database. Ocular adverse effects were classified according to the eye segments and the inflammatory pattern based on the Standardization of Uveitis Nomenclature. Associations among BRAFi monotherapy, MEKi monotherapy, and BRAFi+MEKi combination therapy and OAE reporting were assessed using disproportionality analysis. Results were expressed with the reporting odds ratio (ROR) and its 95% confidence interval (CI). RESULTS: From January 2010 to October 2019, 1568 OAE cases were reported with BRAFi or MEKi. Among them, 1006 cases with sufficient data were included, corresponding to 310 (30.8%), 124 (12.3%), and 572 (56.9%) cases reported with BRAFi, MEKi, or BRAFi+MEKi combination therapy, respectively. BRAF inhibitor monotherapy was significantly associated with the reporting of iris and ciliary body abnormalities (ROR, 8.7; 95% CI, 6.0-12.5), diffuse abnormalities (ROR, 7.1; 95% CI, 5.4-9.4), anterior uveitis (ROR, 8.6; 95% CI, 6.0-12.1), and panuveitis (ROR, 7.1; 95% CI, 5.4-9.4). MEK inhibitor monotherapy was associated with the reporting of retinal and choroid abnormalities (ROR, 9.5; 95% CI, 7.4-12.2), diffuse abnormalities (ROR, 2.5; 95% CI, 1.1-6.1), and panuveitis (ROR, 2.5; 95% CI, 1.1-6.1). Combinations of BRAFi and MEKi therapies were associated with OAEs from both drugs, with a possible synergistic or additive effect for diffuse abnormalities and panuveitis. CONCLUSIONS: Our study characterizes the ocular safety profile of BRAFi and MEKi. We identify possible safety signals for several OAEs not previously reported with BRAFi and MEKi. Our data provide the rationale for a personalized management of OAE in patients with BRAFi+MEKi combination therapy according to the type of ocular reaction.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Mettler C, Monnet D, Kramkimel N, et al. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database. Ophthalmology. 2021. PMID: 34000304. doi:10.1016/j.ophtha.2021.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。